UNSPSC 51182430: Etidronic acid

This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C2H8O7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M2F465ROXU, chemically known as 1,1,1-ethanetriol diphosphonate but generally known as etidronic acid, which bears US NIH Compound Identifier 3305. European Medicines Agency schedules Etidronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07299MIG.

UNSPSC 51182430 Etidronic acid is a Commodity code representing active pharmaceutical ingredients and chemical compounds used in pharmaceutical manufacturing and healthcare delivery. State and local governments procure under this code primarily as components within broader pharmaceutical supply agreements, where etidronic acid serves as an active ingredient in bisphosphonate drugs used to treat bone-related conditions. The issuing bodies soliciting under this code span state cooperative purchasing alliances, state departments of administration, and subordinate participating states and localities. Individual state health departments, county health systems, and municipal facilities typically access etidronic acid and related pharmaceuticals through these cooperative agreements rather than direct procurement.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The procurement covers participating state and local government facilities across Minnesota, Oregon, and other MMCAP member jurisdictions. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Awards are weighted 75 percent on price competitiveness, with evaluation of fixed pricing, administrative fee compliance, EDI capability, and pricing flexibility including flat price, net price formats, and WAC-minus structures. The contract term runs two years from July 1, 2026, with optional extensions at MMCAP's discretion, and vendors face performance penalties ranging from $200 to $1,500 per violation for reporting delays or onboarding failures.